CD1C and cancer: Notably, a recent study showed that small quantities of αGalCer and other α-glycosylceramides can be endogenously produced in mammalian species to modulate the immune response.40 Additionally, CD1d may be an important target for cancer immunotherapy as its high expression was reported on chronic lymphocytic leukaemia cells, correlating with disease progression.41 Similarly, CD1c on acute leukaemia cells was shown to present a novel class of immunogenic self-lipids, called methyl-lysophosphatidic acids (mLPAs).